Literature DB >> 24291734

Neuropathic pain in the general population: a systematic review of epidemiological studies.

O van Hecke1, Sophie K Austin, Rafi A Khan, B H Smith, N Torrance.   

Abstract

Most patients with neuropathic pain symptoms present and are managed in primary care, with only a minority being referred for specialist clinical assessment and diagnoses. Previous reviews have focused mainly on specific neuropathic pain conditions based in specialist settings. This is the first systematic review of epidemiological studies of neuropathic pain in the general population. Electronic databases were searched from January 1966 to December 2012, and studies were included where the main focus was on neuropathic pain prevalence and/or incidence, either as part of a specific neuropathic pain-related condition or as a global entity in the general population. We excluded studies in which data were extracted from pain or other specialist clinics or focusing on specific population subgroups. Twenty-one articles were identified and underwent quality assessment and data extraction. Included studies differed in 3 main ways: method of data retrieval, case ascertainment tool used, and presentation of prevalence/incidence rates. This heterogeneity precluded any meta-analysis. We categorised comparable incidence and prevalence rates into 2 main subgroups: (1) chronic pain with neuropathic characteristics (range 3-17%), and (2) neuropathic pain associated with a specific condition, including postherpetic neuralgia (3.9-42.0/100,000 person-years [PY]), trigeminal neuralgia (12.6-28.9/100,000 PY), painful diabetic peripheral neuropathy (15.3-72.3/100,000 PY), glossopharyngeal neuralgia (0.2-0.4/100,000 PY). These differences highlight the importance of a standardised approach for identifying neuropathic pain in future epidemiological studies. A best estimate of population prevalence of pain with neuropathic characteristics is likely to lie between 6.9% and 10%.
Copyright © 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology; Incidence; Neuropathic pain; Prevalence; Systematic review

Mesh:

Year:  2013        PMID: 24291734     DOI: 10.1016/j.pain.2013.11.013

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  343 in total

1.  TET1 Overexpression Mitigates Neuropathic Pain Through Rescuing the Expression of μ-Opioid Receptor and Kv1.2 in the Primary Sensory Neurons.

Authors:  Qiang Wu; Guihua Wei; Fengtao Ji; Shushan Jia; Shaogen Wu; Xinying Guo; Long He; Zhiqiang Pan; Xuerong Miao; Qingxiang Mao; Yong Yang; Minghui Cao; Yuan-Xiang Tao
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 2.  Topical capsaicin (high concentration) for chronic neuropathic pain in adults.

Authors:  Sheena Derry; Andrew Sc Rice; Peter Cole; Toni Tan; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-01-13

Review 3.  Zonisamide for neuropathic pain in adults.

Authors:  R Andrew Moore; Philip J Wiffen; Sheena Derry; Michael P T Lunn
Journal:  Cochrane Database Syst Rev       Date:  2015-01-22

4.  Nerve injury-induced epigenetic silencing of opioid receptors controlled by DNMT3a in primary afferent neurons.

Authors:  Linlin Sun; Jian-Yuan Zhao; Xiyao Gu; Lingli Liang; Shaogen Wu; Kai Mo; Jian Feng; Weixiang Guo; Jun Zhang; Alex Bekker; Xinyu Zhao; Eric J Nestler; Yuan-Xiang Tao
Journal:  Pain       Date:  2017-06       Impact factor: 6.961

Review 5.  Methadone for neuropathic pain in adults.

Authors:  Ewan D McNicol; McKenzie C Ferguson; Roman Schumann
Journal:  Cochrane Database Syst Rev       Date:  2017-05-17

Review 6.  The Pharmacological Therapy of Chronic Neuropathic Pain.

Authors:  Andreas Binder; Ralf Baron
Journal:  Dtsch Arztebl Int       Date:  2016-09-16       Impact factor: 5.594

7.  Facilitation of MrgprD by TRP-A1 promotes neuropathic pain.

Authors:  Changming Wang; Leying Gu; Yonglan Ruan; Xiao Geng; Miao Xu; Niuniu Yang; Lei Yu; Yucui Jiang; Chan Zhu; Yan Yang; Yuan Zhou; Xiaowei Guan; Wenqin Luo; Qin Liu; Xinzhong Dong; Guang Yu; Lei Lan; Zongxiang Tang
Journal:  FASEB J       Date:  2018-08-27       Impact factor: 5.191

8.  A PROMIS Measure of Neuropathic Pain Quality.

Authors:  Robert L Askew; Karon F Cook; Francis J Keefe; Cindy J Nowinski; David Cella; Dennis A Revicki; Esi M Morgan DeWitt; Kaleb Michaud; Dace L Trence; Dagmar Amtmann
Journal:  Value Health       Date:  2016-04-06       Impact factor: 5.725

Review 9.  Long noncoding RNA (lncRNA): a target in neuropathic pain.

Authors:  Shaogen Wu; Jamie Bono; Yuan-Xiang Tao
Journal:  Expert Opin Ther Targets       Date:  2018-12-02       Impact factor: 6.902

10.  Small-molecule inhibition of STOML3 oligomerization reverses pathological mechanical hypersensitivity.

Authors:  Christiane Wetzel; Simone Pifferi; Cristina Picci; Caglar Gök; Diana Hoffmann; Kiran K Bali; André Lampe; Liudmila Lapatsina; Raluca Fleischer; Ewan St John Smith; Valérie Bégay; Mirko Moroni; Luc Estebanez; Johannes Kühnemund; Jan Walcher; Edgar Specker; Martin Neuenschwander; Jens Peter von Kries; Volker Haucke; Rohini Kuner; James F A Poulet; Jan Schmoranzer; Kate Poole; Gary R Lewin
Journal:  Nat Neurosci       Date:  2016-12-12       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.